Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
COVID-19
Organogenesis Commends Final LCDs
Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage DeterminationCANTON, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE)...
Trinity Biotech Announces Q3 2024 Financial Results
Q3 2024 total revenue of $15.2 million grew +3% Y/Y based on strong demand and output in the TrinScreen HIV...
Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders’ Equity Up 8.8% to $35M
Stable revenue and gross profit despite cost-cutting initiatives, indicating the strength of underlying segments and brands.Solid liquidity position, with cash...
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial – Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed...
Acreage Reports Third Quarter 2024 Financial Results
Launched non-medical sales in Ohio with initial sales accounting for 38% of total state level revenue in Q3 2024Capital infusion...
Healthcare IT Market to Hit USD 834.35 Billion by 2029 with 14.7% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Nov. 14, 2024 /PRNewswire/ -- The global healthcare IT market is projected to reach USD 834.35 billion by 2029...
Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment
PORTAGE, Mich., USA, Nov. 14, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the...
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Combined with Zomedica's eACTH assay, equine veterinarians get same day answers for their PPID and EMS patients ANN ARBOR, MI...
ASTHO Launches Public-Private Advisory Council to Address Critical Public Health Challenges
ARLINGTON, Va., Nov. 13, 2024 /PRNewswire/ -- The Association of State and Territorial Health Officials (ASTHO) has launched an Innovation...
Cosmos Health Issues Letter to Shareholders
CHICAGO, IL / ACCESSWIRE / November 12, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
New Study from Lindus Health Finds Patients are More Likely to Join a Clinical Trial with Telehealth Care
Survey also finds that participants want to know who has access to their health data, and insist on transparency throughout...
WellNow Urgent Care Announces Return to Excellus BlueCross BlueShield Network
Excellus BCBS insurance will be accepted at WellNow Urgent Care effective November 15 EAST SYRACUSE, N.Y., Nov. 12, 2024 /PRNewswire/...
Shineco Announces Reverse Split to Regain NASDAQ Compliance
BEIJING, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic...
Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
CANOPY manuscript preprint includes six-month off-drug follow-up period that highlighted strong protection by pemivibart versus placebo in the immunocompetent Cohort...
Moderna Tops BioSpace’s Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one...
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter€400 million upfront payment from restructured GSK collaboration reflected in financials,...
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
New preclinical data demonstrates that CMV antigens identified with Evaxion’s AI-Immunology™ platform trigger targeted immune responses Results also showcase the...
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance for Microcyn(R)-based Wound Care Hydrogel
BOULDER, CO / ACCESSWIRE / November 11, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing...